Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.70 |
| ▸ | TK2 | O00142 | 4/20 | 0.65 |
| ▸ | TYMP | P19971 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALB | P02768 | 1/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2786143 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL10812613 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL12103839 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL453142 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL14388592 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL22143517 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL2583974 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL10340724 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL10815567 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA | |
| SCHEMBL29299 | 1.00 | PYGM (0.70) | PYGMTK2TYMPALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548486-B1 | New viricide compounds of the general formula: Nu-O-Fa, wherein O represents an oxygen, Nu is a nucleoside or nucleoside analogue, and Fa is an acyl group of mono-unsaturated c18-c20 fatty acid | NORSK HYDRO A.S. (NO) | 2003-04-15 | — | — | US | claimed |
| EP-0350287-B1 | Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use | CHIMERIX INC (US) | 2000-09-27 | — | — | EP | claimed |
| EP-0642525-B1 | Nucleosides being O-acylated with a mono-unsaturated omega-9 C18 or C20 fatty acid | NORSK HYDRO AS (NO) | 1997-05-02 | — | — | EP | claimed |
| EP-0119025-B1 | THYMIDINE KINASE-NEGATIVE TEMPERATURE RESISTANT BOVINE HERPESVIRUS-1 MUTANT AS A VACCINE AGAINST INFECTIOUS BOVINE RHINOTRACHEITIS | Baylor College of Medicine (US) | 1989-09-13 | — | — | EP | claimed |
| JP-62099393-A | — | — | None | — | — | JP | disclosed |
| JP-55149213-A | — | — | None | — | — | JP | disclosed |
| JP-6092988-A | — | — | None | — | — | JP | disclosed |
| EP-3493827-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | Memorial Sloan-Kettering Cancer Center (US) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018027155-A1 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-2814846-A1 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THERAPEUTIC USES THEREOF | Seattle Children's Hospital d/b/a Seattle Children's Research Institute (US) | 2014-12-24 | — | — | EP | disclosed |
| WO-2013123061-A1 | BISPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THERAPEUTIC USES THEREOF | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2013-08-22 | — | — | WO | disclosed |
| EP-2509990-A1 | NOVEL PHOSPH(ON)ATE- AND SULF(ON)ATE-BASED PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-10-17 | — | — | EP | disclosed |
| US-4711850-A | GENETIC ENGINEERING | NOVAGENE, INC. (US) | 1987-12-08 | — | — | US | disclosed |
| US-4703011-A | REMOVAL OF GENE ATTENUATES THE VIRUSE USED IN VACCINES | NOVAGENE, INC. (US) | 1987-10-27 | — | — | US | disclosed |
| EP-0232798-A2 | Pseudorabies virus mutants, vaccines containing same, methods for the production of same and methods for the use of same | NOVAGENE, INC. (US) | 1987-08-19 | — | — | EP | disclosed |
| EP-0226029-A1 | Thymidine kinase deletion mutants of bovine herpesvirus-1, vaccines against infectious bovine rhinotracheitis containing same and methods for the production and use of the same | NOVAGENE, INC. (US) | 1987-06-24 | — | — | EP | disclosed |
| JP-S6299393-A | NOVEL ARABINONUCLEOSIDE PHOSPHOLIPID COMPLEX | TOYO JOZO CO LTD | 1987-05-08 | — | — | JP | disclosed |
| US-4569840-A | Thymidine kinase-negative temperature resistant bovine herpesvirus-1 mutant as a vaccine against infectious bovine rhinotracheitis | BAYLOR COLLEGE OF MEDICINE (US) | 1986-02-11 | — | — | US | disclosed |
| EP-0119025-A2 | Thymidine kinase-negative temperature resistant bovine herpesvirus-1 mutant as a vaccine against infectious bovine rhinotracheitis | Baylor College of Medicine (US) | 1984-09-19 | — | — | EP | disclosed |
| JP-S55149213-A | REMEDY OF DNA FOR VIRAL DISEASE | YAMASA SHOYU CO LTD | 1980-11-20 | — | — | JP | disclosed |